Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase I data for the GS-4774 vaccine confirm tolerability and immunogenicity

Nov. 5, 2013

RINT1 gene mutations linked to early-onset breast cancer

Nov. 5, 2013

Farletuzumab misses phase II endpoint for NSCLC

Nov. 5, 2013

Volasertib inferior to pemetrexed in phase II trial for NSCLC

Nov. 5, 2013

Anti-sclerostin monoclonal antibody shows promise in phase IIa hypophosphatasia trial

Nov. 4, 2013

Model used to predict increase in bone mineral density with DS-9194b

Nov. 4, 2013

Targeting siglec-15 with an antibody reduces bone loss in ovariectomized rats

Nov. 4, 2013

First phase II results reported for MLN-8237 in SCLC

Nov. 4, 2013

Hanmi's HM-61713 effective in phase I NSCLC trial

Nov. 4, 2013

Lurbinectedin shows promise in phase Ib lung cancer trials

Nov. 4, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...